US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome
The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, ...
Disability Scoop3h
FDA Green-Lights First Treatment For Prader-Willi Syndrome
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
BioSpace18h
Soleno Wins First FDA Approval for Hyperphagia in Prader-Willi Syndrome
Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...
MedPage Today on MSN11h
FDA OKs First Drug for Hyperphagia in Prader-Willi Syndrome
Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...
BioPharma Dive1d
First Prader-Willi drug to reduce hunger approved by FDA
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.
Managed Healthcare Executive9h
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...
Zacks Investment Research on MSN17h
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Shares of Soleno Therapeutics SLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR ...
BioWorld8h
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars
Becoming the first treatment for rare genetic disorder Prader-Willi syndrome, breakthrough therapy drug DCCR (diazoxide choline) gained U.S. FDA approval as Vykat XR the evening before its March 27 ...
Healio14h
FDA approves first therapy to treat hyperphagia in Prader-Willi syndrome
The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with Prader-Willi syndrome, Soleno Therapeutics announced. Prader-Willi syndrome is a rare ...
Fierce Pharma15h
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR
Since 2000, when the FDA approved recombinant human growth hormone (rhGH) for those with the rare genetic disorder ...
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndromeManagement to host conference call and webcast today, ...